Client name
Patheon N.V. - target
Other parties involved
Thermo Fisher Scientific Inc.; JLL Partners ; Koninklijke DSM N.V.
Nature of transaction
Thermo Fisher Scientific will commence a tender offer to acquire all of the issued and outstanding shares of Patheon for USD 35.00 per share in cash. The transaction represents a purchase price of approximately USD 7.2 billion, which includes the assumption of approximately USD 2.0 billion of net debt.
Value of transaction
USD 7.2 billion
Date deal
15 May 2017

De Brauw involvement
Co-counsel
Other advisors
Skadden, Arps, Slate, Meagher & Flom (US counsel to Patheon); Morgan Stanley (financial advisor to Patheon); Wachtell, Lipton, Rosen & Katz and NautaDutilh (US and Dutch legal counsel to Thermo Fisher Scientific); Goldman, Sachs & Co. (financial adviser to Thermo Fisher Scientific).

De Brauw lead partner
Paul Cronheim

De Brauw team
Paul Cronheim, Tijmen Klein Bronsvoort, Rick van 't Wout, Mai Nguyen, Eline Viersen, Constantijn Voogt, Paul Sleurink, Tes Flapper, Jeroen van der Schrieck, Frank Hamming, Rein Ferwerda, Janneke van der Kroon, Daniël van Gerven, Inge Doomen